DCLK1 and non-small cell lung carcinoma: DCLK1 (+ 60.2-fold) has been reported to be associated with chemoresistance to cisplatin in non-small cell lung cancer cells and targeting DCLK1 by miR539 led to increased sensitivity to cisplatin (Deng et al. 2018).